Halliburton Co. (NYSE: HAL)�is becoming the king of stock buyback, at least for this week. The oil services giant has announced its preliminary results of the prior modified Dutch auction tender offer that expired on Thursday. Computershare showed that some 100.2 million shares of common stock in Halliburton were validly tendered, including about 28.9 million shares that were tendered through notice of guaranteed delivery.
Halliburton indicated that it now expects to acquire approximately 68 million shares of its common stock in this tender at $48.50 per share. This comes to a total of about $3.3 billion, against a market cap of about $43.7 billion. The preliminary proration factor for the tender offer comes to roughly 67.9%, and the total share count represents 7.4% of Halliburton’s total number issued and outstanding shares.
It was also noted that Halliburton may still repurchase additional shares of its common stock in the future, either in the open market or in privately negotiated transactions. That being said, it cannot repurchase any additional shares until after September 6, 2013, as part of the rules of this tender.
Hot Industrial Conglomerate Companies To Own In Right Now: Celsius Holdings Inc (CELH)
Celsius Holdings, Inc., incorporated on April 26, 2005, is engaged in the development, marketing, sale and distribution of functional calorie-burning beverages under the Celsius brand name. The Company focuses to combine nutritional science with mainstream beverages by using its thermogenic (calorie-burning) MetaPlus formulation. The Company does not directly manufacture its beverages, but instead outsource the manufacturing process to established third-party co-packers. The Company provides its co-packers with flavors, ingredient blends, cans and other raw materials for its beverages purchased by the Company from various suppliers. Celsius, Inc. and Elite FX, Inc. are the wholly owned subsidiaries of the Company.
The Company�� Celsius is a calorie-burning beverage. Celsius is available in seven flavors, lemon-lime, ginger ale, cola, orange and wild berry (which are carbonated) and non-carbonated green tea raspberry/acai and green tea/peach mango. Its beverages are sold in 12 ounce cans, although it has begun to market the ingredients in powdered form in individual On-The-Go packets. The Company�� customer�� include on-the-go women, age 25 to 54, who are looking for a way to burn calories and gain energy with beverages and natural alternatives to diet sodas, as well as sports enthusiasts of both sexes, who are seeking low sodium, preservative-free alternatives. During the year ended December 31, 2009, the Company developed its MetaPlus formulation into a powder that can be mixed with water.
The Company competes with The Coca-Cola Company, Dr. Pepper Snapple Group, PepsiCo, Inc., Nestl茅, Waters North America, Inc., Hansen Natural Corp., and Red Bull.
Advisors' Opinion:- [By John Udovich]
Monster Beverage Corp (NASDAQ: MNST), a mid cap marketer and distributor of energy drinks and alternative beverages, has been a monster of a performer since the end of the financial crisis as the stock is up around 308% over the past five years, but could new or overlooked players like small cap beverage stocks�Jones Soda Co (OTCMKTS: JSDA), Celsius Holdings, Inc (OTCMKTS: CELH) and Konared Corp (OTCBB: KRED) repeat that performance? A look strictly at the long term performance of all three small caps might have you thinking otherwise. After all, none of these small cap beverage stocks are profitable while�the beverage industry can be a long hard expensive slog just to increase market share by one or two points when you are competing for shelf space with industry giants like Pepsi and Coke. But past performance is just that���the past and only part of the story as there is much more to consider about these small cap beverage stocks which could also make them potential acquisition targets by larger beverage players seeking to expand their product line up with innovative products:
Hot Oil Service Stocks To Invest In 2014: Arena Pharmaceuticals Inc.(ARNA)
Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company?s clinical development programs include lorcaserin that has completed two pivotal Phase III clinical trials for the treatment of weight management, including weight loss and maintenance of weight loss; and APD811, which is under Phase I clinical trial for the treatment of pulmonary arterial hypertension. Its preclinical development programs include APD334, for the treatment of autoimmune diseases, including multiple sclerosis and rheumatoid arthritis. The company also researches and develops cannabinoid, receptor agonists for the treatment of osteoarthritis and pain; and GPR119 agonists for the treatment of type 2 diabetes. Its other development programs, which had completed Phase I clinical trial include APD597 for th e treatment of type II diabetes; APD916 for the treatment of narcolepsy and cataplexy; and APD791 for the treatment of arterial thrombosis. In addition, the company provides manufacturing services. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Advisors' Opinion:- [By Brian Orelli]
VIVUS' direct competitors in the obesity space both have large partners. Arena Pharmaceuticals (NASDAQ: ARNA ) secured a marketing deal with Eisai to market Belviq, and Orexigen (NASDAQ: OREX ) will have help from Takeda once its obesity drug, Contrave, is approved.
- [By Keith Speights]
Arena Pharmaceuticals (NASDAQ: ARNA ) and VIVUS (NASDAQ: VVUS ) currently stand as the two drugmakers that fit this bill. VIVUS launched Qsymia in the latter part of 2012, but early sales for the drug were more sluggish than the company had hoped. Arena was held up on launching Belviq as it awaited DEA clearance. However, the company received the go-ahead earlier this month and is now on the market.The prospect of additional reimbursement bodes well for both Arena and VIVUS.
Hot Oil Service Stocks To Invest In 2014: Fifth Street Senior Floating Rate Corp (FSFR)
Fifth Street Senior Floating Rate Corp., incorporated on May 22, 2013, is a closed-end, non-diversified management investment company. The Company investment objective is to maximize the Company�� portfolio�� total return by generating income from its debt investments while seeking to preserve its capital. The Company intends to achieve its investment objective by investing primarily in senior secured loans, including first lien, unitranche and second lien debt instruments, that pay interest at rates, which are determined periodically on the basis of a floating base lending rate, made to private middle market companies whose debt is rated below investment grade, which the Company refer to collectively as senior loans. The Company�� investment adviser is Fifth Street Management.
The Company may also invest in senior unsecured loans issued by private middle market companies and, to a lesser extent, subordinated loans issued by private middle market companies and senior and subordinated loans issued by public companies. Under normal market conditions, at least 80% of the value of its net assets plus borrowings for investment purposes will be invested in floating rate senior loans. Senior loans pay interest at rates, which are determined periodically on the basis of the London-Interbank Offered Rate (LIBOR) plus a premium. Senior loans in which the Company expects to invest are made to United States and, to a limited extent, non- United States corporations, partnerships and other business entities which operate in various industries and geographical regions.
Advisors' Opinion:- [By Marc Bastow]
Management investment company Fifth Street Senior Floating Rate Corp. (FSFR) raised its quarterly dividend 15% to 23 cents per share, payable April 15 to shareholders of record as of March 31.
FSFR Stock�Dividend Yield: 6.88%
Hot Oil Service Stocks To Invest In 2014: Rite Aid Corp (RAD)
Rite Aid Corporation, incorporated in 1968, is a retail drugstore chain in the United States. As of March 3, 2012, the Company operated drugstores in 31 states across the country and in the District of Columbia. As of March 3, 2012, it operated 4,667 stores. In the Company�� stores, it sells prescription drugs and a range of other merchandise, which it calls front end products. During the fiscal year ended March 3, 2012 (fiscal 2012), prescription drug sales accounted for 68.1% of its total sales. The Company carries a range of front end products, which accounted for 31.9% of its total sales in fiscal 2012. Front end products include over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, beverages, convenience foods, greeting cards, seasonal merchandise and other everyday and convenience products, as well as photo processing. It offers a variety of products under its private brands, which contributed approximately 17% of its front end sales in the categories where private brand products were offered in fiscal 2012. As of March 3, 2012, the Company had opened over 2,100 GNC stores-within-Rite Aid-stores. During fiscal 2012, the Company sold two owned operating stores to independent third parties.
During fiscal 2012, its stores filled approximately 295 million prescriptions and served an average of 2.1 million customers per day. The overall average size of each store in its chain is approximately 12,600 square feet. As of March 3, 2012, 60% of its stores were freestanding; 51% of its stores included a drive-thru pharmacy; 24% included one-hour photo shops, and 46% included a GNC store-within-Rite Aid-store. The Company�� customers may also order prescription refills over the Internet through www.riteaid.com, or over the phone through its telephonic automated refill systems for pick up at a Rite Aid store. It has a strategic alliance with GNC, a retailer of vitamin and mineral supplements.
Advisors' Opinion:- [By Adam Levine-Weinberg]
On Thursday morning, Rite Aid (NYSE: RAD ) reported significant improvement in first-quarter earnings. The company reported its third consecutive profitable quarter, with EPS of $0.09, up from a loss of $0.03 per share in the same quarter last year. Results hit the high end of the company's recently updated guidance for EPS of $0.08 to $0.09.
No comments:
Post a Comment